The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Vir Biotechnology Inc (NASDAQ: VIR) was $8.37 for the day, up 1.70% from the previous closing price of $8.23. In other words, the price has increased by $1.70 from its previous closing price. On the day, 0.64 million shares were traded. VIR stock price reached its highest trading level at $8.5 during the session, while it also had its lowest trading level at $8.25.
Ratios:
Our analysis of VIR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.05 and its Current Ratio is at 9.05. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 03 ’24 when De Backer Marianne sold 72,995 shares for $9.46 per share. The transaction valued at 690,365 led to the insider holds 678,457 shares of the business.
HANLY ANN M. sold 2,711 shares of VIR for $27,251 on Apr 01 ’24. The EVP & Chief Technology Officer now owns 132,069 shares after completing the transaction at $10.05 per share. On Mar 27 ’24, another insider, Lee Sung, who serves as the EVP & Chief Financial Officer of the company, sold 6,008 shares for $9.89 each. As a result, the insider received 59,404 and left with 100,492 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 1137014272 and an Enterprise Value of -267648912. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.19 while its Price-to-Book (P/B) ratio in mrq is 0.71. Its current Enterprise Value per Revenue stands at -3.106 whereas that against EBITDA is 0.418.
Stock Price History:
The Beta on a monthly basis for VIR is 0.46, which has changed by -0.6600325 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $27.48, while it has fallen to a 52-week low of $7.61. The 50-Day Moving Average of the stock is -15.82%, while the 200-Day Moving Average is calculated to be -20.51%.
Shares Statistics:
VIR traded an average of 1.06M shares per day over the past three months and 884250 shares per day over the past ten days. A total of 134.78M shares are outstanding, with a floating share count of 88.97M. Insiders hold about 34.50% of the company’s shares, while institutions hold 53.16% stake in the company. Shares short for VIR as of 1713139200 were 5148714 with a Short Ratio of 4.88, compared to 1710460800 on 5430466. Therefore, it implies a Short% of Shares Outstanding of 5148714 and a Short% of Float of 6.2.
Earnings Estimates
The market rating for Vir Biotechnology Inc (VIR) is a result of the insights provided by 7.0 analysts actively involved in the assessment.On average, analysts expect EPS of -$1.05 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.32, while EPS last year was -$1.06. The consensus estimate for the next quarter is -$1.04, with high estimates of -$0.91 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$3.43 and -$4.94 for the fiscal current year, implying an average EPS of -$4.1. EPS for the following year is -$3.98, with 9.0 analysts recommending between -$2.84 and -$5.66.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $39.4M to a low estimate of $2.57M. As of the current estimate, Vir Biotechnology Inc’s year-ago sales were $50.1MFor the next quarter, 6 analysts are estimating revenue of $9.06M. There is a high estimate of $21.3M for the next quarter, whereas the lowest estimate is $4.79M.
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $121.8M, while the lowest revenue estimate was $19.71M, resulting in an average revenue estimate of $40.52M. In the same quarter a year ago, actual revenue was $86.18MBased on 8 analysts’ estimates, the company’s revenue will be $41.61M in the next fiscal year. The high estimate is $106.2M and the low estimate is $17.69M.
